tbuckley/cabot-search huggingface dataset:
Caspase‐cleaved keratin‐18 fragments increase during alcohol withdrawal and predict liver‐related death in patients with alcoholic liver disease
Authors: Sebastian Mueller, Pierre Nahon, Vanessa Rausch, Tessa Peccerella, Ines Silva, Eray Yagmur, Beate K. Straub, Carolin Lackner, Helmut K. Seitz, Pierre Rufat, Angela Sutton, Heike Bantel, Thomas Longerich
Journal: Hepatology (2017)

Noninvasive assessment of disease activity in patients with nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) is still unsettled, but essential for the evaluation of disease progression. We here studied the association of total (M65) and caspase‐cleaved (M30) serum keratin‐18 fragments (n = 204) with histological parameters (n = 106) in heavy drinkers primarily admitted for alcohol withdrawal before and after alcohol detoxification. An age‐, sex‐, and fibrosis‐stage matched NAFLD cohort (n = 30) was used for comparison. The prognostic value of M30 and M65 levels were assessed in an additional prospectively followed‐up cohort of 230 patients with alcoholic cirrhosis (AC) using competing risk analyses. Among the histological parameters, both M30/65 correlated significantly and better than any other serum marker with apoptosis and liver damage, such as ballooning (r = 0.65; P &lt; 0.001), followed by lobular inflammation (0.48; P &lt; 0.001), steatosis (0.46; P &lt; 0.001), but less with fibrosis (0.24; P &lt; 0.001). Area under the receiver operating characteristics curves to detect ballooning, steatosis, or steatohepatitis (SH) were slightly better for M30 ( P &lt; 0.005). Optimal M30 cut‐off values for mild and severe ballooning were 330 and 420 U/L, and 290 and 330 U/L for SH grades 1 and 2. No significant differences of M30/65 were found between the matched NAFLD and ALD cohort. In contrast to aspartate‐amino‐transferase and M65, M30 levels increased significantly from 391 to 518 U/L during alcohol detoxification. Moreover, levels of M30 and M65 predicted non–hepatocellular carcinoma liver‐related mortality in patients with AC during a mean observation interval of 67.2 months. Conclusion : Our data suggest M30 as highly specific marker of liver apoptosis both in ALD and NAFLD. In addition, hepatocellular apoptosis, as determined by M30 levels, occurs during alcohol withdrawal, and survival data point toward a novel underestimated role of apoptosis in patients with ALD. (H epatology 2017;66:96–107).
Histologic Transformation in Marginal Zone Lymphomas
Authors: Silvia Franceschetti, Annarita Conconi, Kathrin Aprile Von Hohenstaufen, Gloria Margiotta Casaluci, Anastasios Stathis, Alden Moccia, Michele Ghielmini, Francesco Bertoni, Gianluca Gaidano, Franco Cavalli, Emanuele Zucca
Journal: Blood (2012)
The Internal-Tandem-Duplication of Flt3 Mutations Augment Chemotaxis in Hematopoietic Cells by Blocking the Down-Regulation of Rho-Associated Kinase That Is Induced by SDF1/CXCR4 Signaling
Authors: Chie Onishi, Satomi Mori, Tomohiro Hirade, Mariko Abe, Seiji Yamaguchi, Reuben Kapur, Seiji Fukuda
Journal: Blood (2012)
Osteoblasts Support Early B Lymphoiesis as well as Stem Cell Proliferation and Myelopoiesis: Identification of the Mammalian Cellular Analog of the Bursa of Fabricius.
Authors: Jiang Zhu, Yi Zhang, Nacksung Kim, Yongwon Choi, Gerard Joe, Russell Taichman, Stephen G. Emerson
Journal: Blood (2004)
In-Vitro Culture of Human CD80/IL2 Lentivirus Transduced Acute Myeloid Leukemia Cells (AML) Promote NK Cell Activation and Cytolytic Activity
Authors: Wendy Ingram, Lucas Chan, Hayrettin Guven, Shahram Kordasti, Linda Barber, Nicola Hardwick, David Darling, Ghulam J Mufti, Farzin Farzaneh
Journal: Blood (2008)
Viral Detection and Cytokine Profile in Early Transient Wheeze and Childhood Asthma
Authors: Masahiko Kato, Shinichi Matsuda, Kazuo Suzuki, Mariko Nukaga, Mayumi Enseki, Hideyuki Tabata, Kota Hirai, Yoshiyuki Yamada, Kenichi Maruyama, Yasuhide Hayashi, Hiroyuki Mochizuki
Journal: Journal of Allergy and Clinical Immunology (2017)

Wheeze is a common respiratory symptom in preschool children. Several clinical parameters, including gestational age at birth, parental atopy, and early-life sensitization, are associated with the development of asthma and are used to differentiate between asthma and transient wheeze in early infancy; however, they are only moderately successful. Here, we investigated respiratory viruses and various cytokines/chemokines in transient wheeze cases and established asthma cases. We analyzed peripheral eosinophil counts, and 27 cytokines/chemokines in acute exacerbations among 14 transient wheeze and 32 asthma cases, controls (no wheeze) aged from 6 months to 6 years, and in non-symptomatic transient wheeze and asthma cases. Viruses were detected using antigen detection kits and/or RT-PCR, followed by direct DNA sequencing analysis. Serum cytokines/chemokines were measured using a multi-cytokine detection system. The two major viruses detected, rhinovirus and respiratory syncytial (RS) virus, were dominant in acute asthma cases. However, RS virus, rhinovirus, human metapneumovirus, parainfluenza virus, coronavirus, and human bocavirus were detected at almost equal levels in transient wheeze cases. Serum IL-4, IL-6, and IL-9 levels were significantly elevated in acute asthma compared with transient wheeze. Conversely, IL-8 and IL-12 values were significantly higher in transient wheeze than in acute asthma. Elevated IL-5 and IP-10 levels compared with controls were significantly higher in acute asthma than in non-symptomatic asthma cases. On the other hand, only IP-10 was significantly higher in transient wheeze than in non-symptomatic transient wheeze cases. Cytokine profiles differ between transient wheeze and childhood asthma.
Variability in prostate volume as determined by MRI versus ultrasound and its impact on treatment recommendations for patients with favorable-risk prostate cancer.
Authors: Yonina R. Murciano-Goroff, Luciant D. Wolfsberger, Arti Parekh, Fiona M. Fennessy, Kemal Tuncali, Peter F. Orio, Thomas Niedermayr, W. Warren Suh, Phillip M. Devlin, Clare M. Tempany, Paul Linh Nguyen
Journal: Journal of Clinical Oncology (2012)

249 Background: Prostate volume affects whether patients qualify for brachytherapy (desired size ≥20mL and ≤60mL) or active surveillance (desired PSA density ≤0.15). This study examines variability in prostate volume as determined by contoured axial ultrasound slices, ultrasound ellipsoid (HxWxL) calculation, and endorectal coil MRI (erMRI) ellipsoid calculation, and quantifies the impact of this variability on treatment recommendations for men with favorable-risk prostate cancer. Methods: The study examined 72 patients who presented consecutively for consideration of brachytherapy for favorable-risk prostate cancer who had 3 volume estimates from direct contouring on ultrasound axial slices (2.5mm thickness), the ultrasound ellipsoid method, and the erMRI ellipsoid method. Results: Average gland size by the contoured ultrasound, ellipsoid ultrasound, and eMRI methods were 34.22, 37.15, and 39.58 mLs, respectively. All pairwise comparisons between methods were significant (all p&lt;0.02). Of the 68 patients who anatomically qualified for brachytherapy on ellipsoid ultrasound measures (size ≥20mL and ≤60mL), 22 (32.35%) did not qualify on eMRI (5 patients &lt;20 mL, 11 patients &gt;60 mL) or contoured ultrasound measures (7 patients &lt;20 mL, 3 patients &gt;60 mL). 40 patients (55.56%) were very low risk (PSA density ≤0.15 ng/dl) as calculated using ellipsoid ultrasound volumes, while 35 (48.61%) and 39 patients (54.17%) were very low risk using contoured ultrasound and eMRI volumes, respectively. Conclusions: The ultrasound ellipsoid and erMRI ellipsoid methods appeared to overestimate ultrasound contoured volume by an average of 8.56% and 15.65% respectively. 32.35% of those who qualified for brachytherapy based on ellipsoid ultrasound volume would be disqualified based on ultrasound contoured and/or erMRI volume. As treatment recommendations increasingly rely on estimates of prostate size, clinicians must consider method of volume estimation.
Association of early tumor shrinkage with progression-free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSG0802.
Authors: Hiroshi Nakatsumi, Satoshi Yuki, Tetsuhito Muranaka, Hiraku Fukushima, Takashi Kato, Takashi Meguro, Michio Nakamura, Ichiro Iwanaga, Nobuyuki Ehira, Norikazu Sonoda, Mineo Kudo, Kanji Kato, Kencho Miyashita, Masakazu Abe, Noriyuki Miyamoto, Keita Sakamoto, Kohsuke Kudo, Naoya Sakamoto, Yuh Sakata, Yoshito Komatsu
Journal: Journal of Clinical Oncology (2015)

749 Background: It was reported that early tumor shrinkage (ETS) was associated with better overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) receiving cetuximab. We investigated association of ETS with progression free survival (PFS) in pts with unresectable colorectal liver metastases (CLM) from HGCSG0802 observational cohort study in pts with mCRC treated with first-line bevacizumab (BV)-based chemotherapy. Methods: The objective of HGCSG0802 was to evaluate PFS, OS, time to treatment failure (TTF), response rate (RR), safety and so on. The key eligibility criteria were evaluable lesions, older than 20 years old, ECOG PS 0-2. In this analysis, association of ETS at 8 weeks from the start of chemotherapy with pts characteristics, PFS and TTF was evaluated. Pts characteristics were compared using Student-t test, chi-square test and Fisher’s exact test. PFS and TTF were analyzed with Kaplan-Meier method and compared using log-rank test. Univariate analysis for the association of pts characteristics with PFS and TTF was performed using log-rank test, and multivariate analysis was performed using Cox proportional hazards model. Results: Of 108 pts (the full analysis set), 74 pts with CLM were evaluable for ETS. Forty-nine pts (66.2%) had ETS ≥20%. The pts characteristics between ETS ≥20% and &lt;20% were well balanced. The median PFS was 7.3 months in ETS &lt;20% versus 10.0 months in ETS ≥20% (HR 0.55; p=0.025). In multivariate analysis for PFS, there was no significant difference between ETS ≥20% and &lt;20% (HR 0.585; p=0.066). The median TTF (ETS &lt;20% v ≥20%) was 5,1 months vs. 7.7 months (HR 0.46; p=0.003). In multivariate analysis for TTF, there was significant difference between ETS ≥20% and &lt;20% (HR 0.509; p=0.017). Conclusions: In this analysis, ETS ≥20% might be positive predictive marker for PFS and TTF in pts with CLM receiving first-line BV-based chemotherapy.
Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment
Authors: Niels Weinhold, Shweta S. Chavan, Leo Rasche, Owen W Stephens, Purvi Patel, Ruslana Tytarenko, Cody Ashby, Caleb K. Stein, Michael A Bauer, Christopher P Wardell, Shayu Deshpande, Timea Buzder, Gabor Molnar, Frits van Rhee, Maurizio Zangari, Sharmilan Thanendrarajan, Brian A Walker, Shmuel Yaccoby, Sarah K. Johnson, Joshua Epstein, Bart Barlogie, Christoph Heuck, Faith E Davies, Tobias Meissner, Gareth J Morgan
Journal: Blood (2016)
Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis
Authors: L. Pizzuti, I. Sperduti, A. Michelotti, C. Omarini, T. Gamucci, C. Natoli, L. D'Onofrio, F. Giotta, C. Ficorella, L. Laudadio, A. Cassano, P. Marchetti, V. Adamo, M. Mauri, A.F. Scinto, G. Zampa, A. Fabbri, L. Mentuccia, S. Barni, P. Vici
Journal: Annals of Oncology (2016)
MDR1 gene expression in peripheral blood as a marker of treatment response in lung cancer.
Authors: Raquel Luque, Encarnacion Gonzalez Flores, Juan Ramon Delgado, Consolación Melguizo, Jose Carlos Prados, Beatriz Gonzalez Astorga, Raul Ortiz, Carmen Sánchez Toro, Javier Valdivia, Antonia Aránega
Journal: Journal of Clinical Oncology (2012)

96 Background: Non-small cell lung cancer (NSCLC) is sometimes chemoresistant and does not respond to treatment; several factors are involved in the development of chemoresistance, such as multidrug resistance (MDR) phenotype, mainly. Methods: We studied MDR1 gene expression in peripheral blood PMN of 23 patients with NSCLC, advanced stages in most of the cases, who had not received treatment previously, before (hour 0) and after (hour 6) paclitaxel-carboplatin treatment. RNA was obtained from PMN pellet by means of the protocol of trizol. RNA was checked with agarose gels, and later RT-PCR technique was carried out using specific primers. Expression levels were randomly distributed, so that overexpression under 3 was considered low level of expression, and overexpression above 4 was considered high level of expression. Results: After treatment, we found overexpression of MDR1 in 22 patients. High levels were found in 11 patients, and low levels were observed in the other 11 patients. No relation was found between this fact and the treatment response or survival rate. No significant differences in expression were found in the other variables: gender, tobacco habit, weight loss at the diagnosis, tumour staging, and tumor histology. Conclusions: We can conclude that MDR1 expression in peripheral blood is not a predictive factor for treatment response nor a prognostic factor of the disease. Despite these results, further studies are necessary on molecular biology of NSCLC in order to try to establish subgroups of patients based on genetic profiles, in which the use of microarrays could be very useful.
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
Authors: R. Coleman Lindsley, Wael Saber, Brenton G. Mar, Robert Redd, Tao Wang, Michael D. Haagenson, Peter V. Grauman, Zhen-Huan Hu, Stephen R. Spellman, Stephanie J. Lee, Michael R. Verneris, Katharine Hsu, Katharina Fleischhauer, Corey Cutler, Joseph H. Antin, Donna Neuberg, Benjamin L. Ebert
Journal: New England Journal of Medicine (2017)

Genetic mutations drive the pathogenesis of the myelodysplastic syndrome (MDS) and are closely associated with clinical phenotype. Therefore, genetic mutations may predict clinical outcomes after allogeneic hematopoietic stem-cell transplantation.We performed targeted mutational analysis on samples obtained before transplantation from 1514 patients with MDS who were enrolled in the Center for International Blood and Marrow Transplant Research Repository between 2005 and 2014. We evaluated the association of mutations with transplantation outcomes, including overall survival, relapse, and death without relapse.TP53 mutations were present in 19% of the patients and were associated with shorter survival and a shorter time to relapse than was the absence of TP53 mutations, after adjustment for significant clinical variables (P<0.001 for both comparisons). Among patients 40 years of age or older who did not have TP53 mutations, the presence of RAS pathway mutations was associated with shorter survival than was the absence of RAS pathway mutations (P=0.004), owing to a high risk of relapse, and the presence of JAK2 mutations was associated with shorter survival than was the absence of JAK2 mutations (P=0.001), owing to a high risk of death without relapse. The adverse prognostic effect of TP53 mutations was similar in patients who received reduced-intensity conditioning regimens and those who received myeloablative conditioning regimens. By contrast, the adverse effect of RAS pathway mutations on the risk of relapse, as compared with the absence of RAS pathway mutations, was evident only with reduced-intensity conditioning (P<0.001). In young adults, 4% of the patients had compound heterozygous mutations in the Shwachman-Diamond syndrome-associated SBDS gene with concurrent TP53 mutations and a poor prognosis. Mutations in the p53 regulator PPM1D were more common among patients with therapy-related MDS than those with primary MDS (15% vs. 3%, P<0.001).Genetic profiling revealed that molecular subgroups of patients undergoing allogeneic hematopoietic stem-cell transplantation for MDS may inform prognostic stratification and the selection of conditioning regimen. (Funded by the Edward P. Evans Foundation and others.).
QLIF-20. A CROSS-SECTIONAL STUDY OF DISTRESS THROUGHOUT THE DISEASE TRAJECTORY IN PRIMARY BRAIN TUMOR PATIENTS
Authors: Dina Randazzo, Frances McSherry, James Herndon, Mary Lou Affronti, Eric Lipp, Charlene Flahiff, Elizabeth Miller, Sarah Woodring, Maria Freeman, Patrick Healy, Janet Minchew, Susan Boulton, Annick Desjardins, Gordana Vlahovic, Henry Friedman, Stephen Keir, Katherine Peters
Journal: Neuro-Oncology (2016)

Primary brain tumor patients experience a high level of psychosocial distress due to their diminished functional and neurocognitive capacities and ultimately bear the stigma of being a brain cancer patient. The purpose of this study is to evaluate the level of distress throughout the disease trajectory of a primary brain tumor patient. Within this cross-sectional study, the National Comprehensive Cancer Network’s Distress Thermometer (NCCN-DT) and problem list were collected from patients seen between December 2013 and February 2016 at The Preston Robert Tisch Brain Tumor Center at Duke, along with demographic and clinical information. Among the 829 subjects, 798 (96.3%) completed the DT, 54.0% were male, and 69.5% had high grade glioma (HGG). Significant distress (≥4) was reported by 46.2%, 33.3%, 24.2%, 34.0%, and 32.3% of patients assessed 0-6 months, 6-12 months, 1-2 years, 2-5 years, and >5 years after initial diagnosis. 117 patients were assessed during the 6 months after initial diagnosis: 6.0% recurrent disease, 81.2% HGG, and 63.2% with age ≥50 years. Of these patients, 46.2% reported significant distress; 47.4% of HGG and 41.2% of low grade glioma (LGG) patients reported distress. 153 patients were assessed 1-2 years after diagnosis: 51.6% recurrent disease, 75.2% HGG, and 53.6% with age ≥50 years. Of these patients, 24.2% reported significant distress; 23.5% of HGG, 24.1% of LGG, and 30.4% of recurrent patients reported distress. The median number of problems reported decreased from 6 at 0-6 months to 2-3 at ≥1 year after diagnosis. Primary brain tumor patients experience distress throughout their disease trajectory, but the 6 months after initial diagnosis is the most stressful. A longitudinal study assessing distress in glioma patients may be helpful in ascertaining the periods of greatest distress and greatest need for interventions.
Epicutaneous sensitization to house dust mite allergen requires interferon regulatory factor 4–dependent dermal dendritic cells
Authors: Julie Deckers, Dorine Sichien, Maud Plantinga, Justine Van Moorleghem, Manon Vanheerswynghels, Esther Hoste, Bernard Malissen, David Dombrowicz, Martin Guilliams, Karolien De Bosscher, Bart N. Lambrecht, Hamida Hammad
Journal: Journal of Allergy and Clinical Immunology (2017)
R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433
Authors: Jonathan W. Friedberg, Joseph M Unger, W. Richard Burack, Ajay K Gopal, Michael LeBlanc, Oliver W. Press, Thomas P. Miller, Richard I Fisher
Journal: Blood (2010)
Molecular Analysis of Posttransplant Lymphoproliferative Disorders (PTLD) of Donor Origin Occuring in Liver Transplant Patients.
Authors: Daniela Capello, Giuliana Muti, Michaela Cerri, Davide Rossi, Pierluigi Oreste, Enrica Morra, Gianluca Gaidano
Journal: Blood (2005)
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis
Authors: Simona Soverini, Caterina De Benedittis, Michela Rondoni, Cristina Papayannidis, Elisa Ficarra, Giulia Paciello, Marco Manfrini, Manuela Mancini, Roberta Zanotti, Luigi Scaffidi, Giorgina Specchia, Francesco Albano, Serena Merante, Chiara Elena, Livio Pagano, Domenica Gangemi, Patrizia Tosi, Luana Bavaro, Maria Chiara Fontana, Viviana Guadagnuolo, Alberto Ferrarini, Elisa Zago, Michele Cavo, Massimo Delledonne, Peter Valent, Giovanni Martinelli
Journal: Blood (2016)
ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma
Authors: Matteo Marchesini, Yamini Ogoti, Elena Fiorini, Marianna D'anca, Paola Storti, Luigi Nezi, Mehmet K. Samur, Irene Gañán-Gómez, Mariateresa Fulciniti, Zachary S. Bohannan, Karen Clise-Dwyer, Nicola Giuliani, Nikhil C Munshi, Robert Z. Orlowski, Guillermo Garcia-Manero, Ronald A. DePinho, Simona Colla
Journal: Blood (2016)
Lenalidomide Enhances Multiple Myeloma Cytotoxicity Induced by a Novel Fc Domain-Engineered Anti-HM1.24 Monoclonal Antibody with Augmented NK Cell Degranulation
Authors: Sun-Young Kong, Sabikun Nahar, Xian-Feng Li, Weihua Song, Yiguo Hu, Umesh Muchhal, John Desjarlais, Paul Richardson, Nikhil C. Munshi, Kenneth C. Anderson, Yu-Tzu Tai
Journal: Blood (2010)
Validation of Comorbidity Indexes in Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation. the Hematopoietic Cell Transplantation Comorbidity Index Is the Best Predictor of NRM and Survival.
Authors: Pere Barba, Jose Luis Piñana, Alex Amoros, David Valcárcel, Rodrigo Martino, Anna Sureda, Javier Briones, Julio Delgado, Miquel Granell, Salut Brunet, Ma. Rosa Suñol, J. Sierra
Journal: Blood (2008)
Rebiopsy of patients (pts) with acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC)
Authors: M. E. Arcila, G. J. Riely, M. F. Zakowski, M. G. Kris, M. Ladanyi, W. Pao, V. A. Miller
Journal: Journal of Clinical Oncology (2009)

8025 Background: The EGFR-TKIs erlotinib and gefitinib produce dramatic regressions of tumor in ∼ 70% of NSCLC patients with activating mutations in the EGFR-TK domain. After a median time to progression of ∼1 year, most pts have progressive disease. We undertook this study to search for mechanisms of “acquired resistance” to EGFR-TKIs, to determine the spectrum and frequency of secondary EGFR mutations which arose, and to determine the feasibility of rebiopsy in this setting. Methods: All pts had metastatic or recurrent NSCLC and prior treatment with EGFR-TKI and progressive disease while on EGFR-TKI. Pts must also have had an activating EGFR mutation OR radiographic response (RECIST or WHO) to EGFR-TKI OR significant and durable improvement in cancer-related symptoms as judged by patient's physician. Core biopsies were performed and studied for EGFR mutation (exons 18–21 including PCR-based test for T790M) and MET amplification. Results: From 8/04–12/08 98 pts were consented for rebiopsy and 85 underwent the procedure. Demographics Female/Male=59/39; median age 62 (range 28–88); smoking: never=59, former/current=39. Primary EGFR mutation was exon 19 del-39; exon 21 L858R-11, other/WT-28, pending-7. Median time on EGFR-TKI before biopsy was 12 months (7–28 months). Secondary EGFR mutations: T790M-33, other-2, none detected-31, indeterminate-10, pending-9. MET amplification in 2/16 studied to date. Conclusions: 1) Rebiopsy of patients with NSCLC and acquired resistance to EGFR TKIs is feasible and well-received by pts. 2) Knowledge of EGFR genotype including EGFR T790M and MET status can inform clinical trials of targeted therapies in this population 3) More complete annotation of MET status and exploratory analyses of profiles of specimens by metastatic sites and prior EGFR-TKI versus chemo and EGFR-TKI is ongoing. Supported by the Doris Duke Foundation, the LaBrecque Foundation, Steps for Breath, NIH, and an anonymous donor. No significant financial relationships to disclose.
Regadenoson, An Adenosine 2A Receptor Agonist, Is Safe and Inhibits Invariant NKT Cells in Sickle Cell Disease
Authors: Joshua Field, Gene Lin, Maureen Okam, Elaine Majerus, Onyinye Onyekwere, Ainsley Ross, Donna Neuberg, Federico Campigotto, David G. Nathan, Joel Linden
Journal: Blood (2011)